105 related articles for article (PubMed ID: 6165469)
1. Combination of vinblastine and bleomycin in metastatic renal cell carcinoma.
Knost JA; Oldham RK; Hande KR; Rhamy RK; Greco FA
Cancer Treat Rep; 1981; 65(3-4):349-50. PubMed ID: 6165469
[No Abstract] [Full Text] [Related]
2. Pilot study of vinblastine and bleomycin combinations in the treatment of metastatic melanoma.
Nathanson L; Wittenberg BK
Cancer Treat Rep; 1980 Jan; 64(1):133-7. PubMed ID: 6155208
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate with leucovorin rescue, vinblastine, and bleomycin with or without tamoxifen in metastatic renal cell carcinoma.
Bell DR; Aroney RS; Fisher RJ; Levi JA
Cancer Treat Rep; 1984 Apr; 68(4):587-90. PubMed ID: 6201268
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma.
Kuebler JP; Hogan TF; Trump DL; Bryan GT
Cancer Treat Rep; 1984 Jun; 68(6):925-6. PubMed ID: 6733709
[No Abstract] [Full Text] [Related]
5. Cisplatin, vindesine, and bleomycin (DVB) combination chemotherapy for esophageal carcinoma.
Kelsen DP; Bains M; Chapman R; Golbey R
Cancer Treat Rep; 1981; 65(9-10):781-5. PubMed ID: 6168370
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of combination methyl-GAG and vinblastine in the treatment of metastatic renal adenocarcinoma.
Todd RF; Garnick MB; Canellos GP
Cancer Treat Rep; 1982 Jul; 66(7):1585-6. PubMed ID: 7093973
[No Abstract] [Full Text] [Related]
7. Single-agent therapy for renal cell carcinoma: CCNU, vinblastine, thioTEPA, or bleomycin.
Hahn DM; Schimpff SC; Ruckdeschel JC; Wiernik PH
Cancer Treat Rep; 1977 Nov; 61(8):1585-7. PubMed ID: 72603
[No Abstract] [Full Text] [Related]
8. [Chemotherapy of renal cell carcinoma. 2. Combined chemotherapy using ACNU and VBL].
Kobayashi M; Imai K; Nakai K; Kumasaka F; Suzuki T; Ito Y; Yamanaka H; Sugihara S
Hinyokika Kiyo; 1986 Mar; 32(3):375-83. PubMed ID: 3460318
[TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy of renal cell carcinoma. 3. Single-agent therapy with FT-207 or vinblastine].
Satomi Y; Senga Y; Fukuda M; Nakahashi M; Ohshima H; Furuhata A
Nihon Hinyokika Gakkai Zasshi; 1984 Jun; 75(6):903-8. PubMed ID: 6438382
[No Abstract] [Full Text] [Related]
10. Failure of 5-day vinblastine infusion in the treatment of patients with renal cell carcinoma.
Tannock IF; Evans WK
Cancer Treat Rep; 1985 Feb; 69(2):227-8. PubMed ID: 3882231
[No Abstract] [Full Text] [Related]
11. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of vindesine sulfate in the therapy for advanced renal carcinoma.
Wong PP; Yagoda A; Currie VE; Young CW
Cancer Treat Rep; 1977 Dec; 61(9):1727-9. PubMed ID: 340038
[No Abstract] [Full Text] [Related]
13. Combination chemotherapy of esophageal carcinoma using cisplatin, vindesine, and bleomycin.
Kelsen DP; Bains M; Hilaris B; Chapman R; McCormack P; Alexander J; Hopfan S; Martini N
Cancer; 1982 Mar; 49(6):1174-7. PubMed ID: 6174199
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer.
Hahn RG; Begg CB; Davis T
Cancer Treat Rep; 1981; 65(7-8):711-13. PubMed ID: 7018680
[TBL] [Abstract][Full Text] [Related]
15. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network.
Haas NB; Giantonio BJ; Litwin S; Minniti CJ; Fox S; Yeslow G; Reilly R; Nahum K; Greenberg R; Halbherr T; Hudes GR
Cancer; 2003 Nov; 98(9):1837-41. PubMed ID: 14584064
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma.
Van Echo DA; Markus S; Aisner J; Wiernik PH
Cancer Treat Rep; 1980; 64(8-9):1009-10. PubMed ID: 6893810
[No Abstract] [Full Text] [Related]
17. Phase II evaluation of vindesine in non-small cell bronchogenic carcinoma.
Hutcheon AW; Palmer JB; Pratt MA; Clark RA
Cancer Treat Rep; 1983 Nov; 67(11):1041-2. PubMed ID: 6315231
[No Abstract] [Full Text] [Related]
18. Phase II study of amsacrine in metastatic renal cell carcinoma: a Cancer and Leukemia Group B study.
Amrein PC; Coleman M; Richards F; Poulin RF; Berkowitz I; Kennedy BJ; Green M; Herschkopf R; Rafla S
Cancer Treat Rep; 1983 Nov; 67(11):1043-4. PubMed ID: 6688967
[No Abstract] [Full Text] [Related]
19. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
Kyriakakis Z; Dimopoulos MA; Kostakopoulos A; Karayiannis A; Sofras F; Zervas A; Giannopoulos A; Dimopoulos C
J Urol; 1997 Aug; 158(2):408-11. PubMed ID: 9224313
[TBL] [Abstract][Full Text] [Related]
20. Inclusion of cisplatinum (cis-DDP, Platidiam, Lachema) into combined chemotherapeutic protocol for the treatment of testicular cancer.
Bodrogi I; Baki M; Hindy I; Eckhardt S
Neoplasma; 1983; 30(5):557-61. PubMed ID: 6197662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
